Skip to main content

Year: 2021

Harvia Finland acquired an industrial building next to the Muurame factory

Harvia Finland Oy has purchased an industrial building of 1,266 square meters and the lease of the plot of land next to its Muurame factory with a deed signed on December 1st, 2021. The acquired building is suitable for production use, but for the time being the company will use it as part of its own logistics and warehousing operations. Harvia’s objective is to redeem the property’s 4,500-square-meter plot from the municipality of Muurame still this year. In the summer of 2022, the property’s plot will be merged into the current factory yard area.Further information: CEO Tapio Pajuharju, tapio.pajuharju@harvia.fi, tel. +358 50 577 4200 CFO Ari Vesterinen, ari.vesterinen@harvia.fi, tel. +358 40 505 0440Harvia is one of the leading companies operating in the sauna and spa market globally, as measured by revenue. Harvia’s...

Continue reading

BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has filed ten patent applications related to its BRTX-100 program for treating chronic lumbar disc disease with the United States Patent and Trademark Office (USPTO). The patent applications are directed towards methods of manufacturing stem cells that are engineered to survive avascular zones (areas where there is little blood flow and nutrients). The ability for cells to survive these harsh environments is critical for cell-based therapies. “When treating disorders such as chronic lumbar disc disease, where the cellular micro-environment has a low oxygen and nutrient supply, cell survival must be accounted...

Continue reading

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 – 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated to a TLR7/8 agonist with a non-cleavable linker. “The data we will be presenting at ESMO I-O includes more than 50 patients at increasing...

Continue reading

Check Point Software Technologies Named a Worldwide Major Player in Modern Endpoint Security for Enterprise & SMB in latest IDC MarketScape Reports

Check Point Harmony Endpoint highlighted for distinctive endpoint security capabilities, broad product portfolio, history of profitability and access to consumer sector SAN CARLOS, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, has been recognized as a Major Player in two reports recently released by IDC research: IDC MarketScape Worldwide Modern Endpoint Security 2021 Vendor Assessment for Enterprise 2021 Vendor Assessment (Doc # US48306021, November 2021), and IDC MarketScape Worldwide Modern Endpoint Security 2021 Vendor Assessment for Small Medium Size business 2021 Vendor Assessment (Doc # US48304721, November 2021). Modern endpoint security (MES) technology is the combination of endpoint protection platforms (EPPs) for...

Continue reading

New Jam Studio VR Expanded Compatibility

Valve Index, Oculus Quest & Rift, HTC Vive, Focus & Flow, Windows MR & More SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Beamz Interactive, Inc., a leading developer of state-of-the-art interactive music technology and products, today announced expanded compatibility for its Jam Studio VR & Jam Studio VR Education & Health Care Editions. This now includes compatible with the Valve Index, Oculus Quest, Oculus Rift, HTC Vive, Flow, Focus and Enterprise, and Windows MR Headsets and Controllers on Steam and/or Viveport as well as compatibility with the Quest Stand Alone Headset in App Labs (see https://tinyurl.com/tr7h2e6f). These interactive Music, Education, and Health Care Apps (see www.jamstudiovr.com) immerse you in a world of music where you interact with virtual musical instruments pre-loaded with...

Continue reading

NDTV Convergence Signs Exclusive 10-Year Deal with Taboola

NDTV Convergence’s Exclusive 10-Year, 750-Crore Deal with Taboola Among Largest-ever Ad Deals in APAC, NDTV Adopts All Taboola Publisher Offerings NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, helping people discover things they may like, today announced a 10-year deal with NDTV Convergence, reaffirming its position as India’s leading platform for online news. The decade-long deal is based on mutually-determined projections, including growth in traffic, and cumulatively can enable revenue of Rs. 750 crores or 100 million dollars for NDTV Convergence contingent upon it meeting the targets assigned for different stages of the 10-year period. Ndtv.com has nearly 200 million uniques and is known for the fastest online news and best user experience in...

Continue reading

Ascent Solar Issues Update on Reverse Stock Split Process

THORNTON, CO, Dec. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Ascent Solar Technologies, Inc. (OTCMKTS: ASTI), a developer and manufacturer of state-of-the-art, lightweight and flexible thin-film photovoltaic (PV) solutions (“Ascent Solar”, “Ascent” or the “Company”), today released an update on its previously announced and pending process for a proposed reverse stock split (“Reverse Split”). The Company filed its definitive 14C information statement relating to the Reverse Split with the SEC on November 29, 2021, and such information statement is currently being mailed to the Company’s stockholders. Under SEC rules, the Reverse Split cannot be implemented before December 20, 2021. The Reverse Split is also subject to regulatory review by FINRA. The Company intends to implement the Reverse Split as soon as possible after...

Continue reading

Qutoutiao Inc. Announces Plan to Implement ADS Ratio Change

SHANGHAI, China, Dec. 02, 2021 (GLOBE NEWSWIRE) — Qutoutiao Inc. (“Qutoutiao” or the “Company”) (NASDAQ: QTT), a leading operator of mobile content platforms in China, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its Class A ordinary shares (the “ADS Ratio”), par value US$0.0001 per share, from the current ADS Ratio of four (4) ADSs to one (1) Class A ordinary share to a new ADS Ratio of two (2) ADSs to five (5) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on or about December 10, 2021. For Qutoutiao’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split. Each ADS holder of record at the close of business on the date when the change in ADS Ratio is effective will be required...

Continue reading

Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

Dr. Jules Mitchel now leading preparation for data lock and statistical analysis Business update call Today at 4:30PM ESTNew York, NY, and Tel Aviv, ISRAEL, Dec. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL biology-focused joint venture partner NLC Pharma, today announced that all 31 patients enrolled to date in Tollovir® Phase 2 clinical trial in hospitalized COVID-19 patients have completed study participation and the data are now being entered into the database for analysis. Dr. Jules Mitchel, a strategic advisor retained by Todos to assist with the analysis, is now leading preparation for data lock and statistical analysis. The Company expects data analysis to be completed in December 2021. The...

Continue reading

CNH Industrial acquires software engineering specialist NX9

This investment continues to advance the Company’s ISOBUS capabilities for core agriculture products. London, December 2, 2021 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has acquired NX9, a software suite specialized in delivering ISOBUS core technologies and applications for agricultural equipment, and related intellectual property rights. This latest R&D investment builds upon the Company’s strategic impetus to more efficiently innovate and develop products in the precision agriculture space and deliver greater value for its farming customers. The acquisition marks a further step in consolidating in-house digital agriculture competencies that enrich product, brand, distribution and supply chain strength. It will openly integrate streamlined ISOBUS capabilities across the electrical vehicle architecture of CNH...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.